United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
CAMBRIDGE, Mass., Nov. 09, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at two upcoming investor conferences in November:
- Stifel 2016 Healthcare Conference: Corporate presentation at 11:45 a.m. ET on Wednesday, November 16, 2016 in New York, NY.
- Piper Jaffray 28th Annual Healthcare Conference: Fireside chat at 12:00 p.m. ET on Wednesday, November 30, 2016 in New York, NY.
A live webcast of these presentations can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcasts will be archived for 30 days following the presentation.
About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended), and earlier-stage investments in cancer immunotherapy. Genocea also has earlier stage research programs in chlamydia, genital herpes and malaria which were paused in the fourth quarter of 2016. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
